Hi, Very interesting. Can you please tell us about your IP portfolio? Thanks. Blessings

Thank you for your question. We have exclusive worldwide rights to the patents that we need for Simplify and the right to prosecute those patents. Please don't hesitate to let me know if you have more questions. Thank you for your consideration.

Dear Sirs, I am Giovanni Diamante and I have tried to file an investment in Simplified Genomics, but I cannot close it to send it to you. What I am missing? Regards, Giovanni gfdiamante@yahoo.com

Giovanni - are you still having issues? I can talk to Wefunder about having someone follow-up with you. Thank you.

Hello Travis, Greetings! Love your initiative. I am an Angel investor. Have few questions - Is there a liquidation preference or preference overhang in the cap table? - Given the uniqueness of the platform, wonder why Human Longevity is your only customer? Where do you see the...

No overhang or liquidation preference in the cap table - standard common and preferred. On the Human Longevity question, we are now bringing on new customers but it has all been through word of mouth. Part of use of funds will be to expand commercially - we are also launching in 1Q w a large imaging center combining our WG report with their WB MRI (cash pay). The revenue decline was all due to us continuing to bring our prices down to a point where we can drive more volume. At the same time, ...

I am an obstetrician/gynecologist and a functional medicine practitioner since 2005. I did my first microarray for methylation pathway with Dr Amy Yasko in 2005 and HLA gene typing in 2010 and have been practicing nutrigenomics since then with great relief of some symptoms, so...

Hi Bina, thanks for your interest and questions. We are excited about where we can take this company and our approach to scientifically-based preventative care. HLA-typing and methylation are areas of interest to us, but we must stay focused in the short term. I would like to address your specific questions. 1. For clinical genome interpretation, we rely on scientific findings from published studies, public and licensed genomic data sources, and our internal proprietary data. This allows us t...

I assume your company has patents regarding your technology. If so, I would add a section about that on Wefunder unless I missed it as I read through. If you do, roughly what does it cover/how do they set your company apart from any competitors?

Thank you for your question and suggestion. Yes we have been given exclusive worldwide license on the patents around our Search engine that allow users to search raw genomic and clinical information in a quick and efficient manner. The ability to upload thousands of whole genomes, get that information organized, and enable non-technical users to search that information in “google speed” is a huge differentiator from what is available on the market today. I would be happy to discuss further an...

Simplify Genomics Updates, Team, and Funding Progress | Wefunder, Home of the Community Round

CAP-accredited, CLIA-certified clinical genomics company powered by Smart Genome technology

More than 50,000 whole genomes processed and over 10,000 clinical reports issued

Built for a market where clinical interpretation remains the bottleneck of whole genome sequencing

Grown from two to fifteen clinical customers on word of mouth, with no outbound sales team

Collaboration announced with SimonMed, a network of more than 175 imaging centers

Smart Genome platform developed across nine major releases, with continued product expansion planned

Spun out of Human Longevity with core technology, data assets, and $90M in prior development

$4.9M raised from 2,819 investors in our prior round

Simplify Genomics

Trusted Clinical Genomics for Healthcare Partners

Never miss an update

What Investors Say

Simplify Genomics

Quick facts

Team profiles

Featured investor profiles

Never miss an update

What Investors Say